Climacteric obesity: From genesis to clinic

Gynecological Endocrinology

Volumn 22, Issue 1, 2006, Pages 18-24

  Milewicz, Andrzej ^a,b   Jedrzejuk, Diana ^a  

^a WROCLAW MEDICAL UNIVERSITY   (Poland)

^b Department of Endocrinology Diabetology and Isotope Treatment ^*  (Poland)

Author keywords

Climacteric obesity; Fat distribution; Obesity

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR; CHOLECYSTOKININ; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ESTROGEN RECEPTOR ALPHA; GALANIN; GROWTH HORMONE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LEPTIN; METFORMIN; NEUROPEPTIDE Y; PEPTIDE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PRASTERONE; RESISTIN; SEX HORMONE;

ABDOMEN; ADRENERGIC SYSTEM; AGING; ALGORITHM; CARDIOVASCULAR DISEASE; CLIMACTERIC OBESITY; CLINICAL TRIAL; CONCENTRATION (PARAMETERS); DIAGNOSTIC PROCEDURE; DOSE RESPONSE; DRUG EFFECT; ENDOCRINOLOGY; EVIDENCE BASED MEDICINE; FEMALE; GENETIC POLYMORPHISM; HEREDITY; HIGH RISK PATIENT; HUMAN; HUNGER; MENOPAUSAL SYNDROME; METABOLIC DISORDER; METABOLISM; MOLECULAR BIOLOGY; NERVOUS SYSTEM FUNCTION; NEUROENDOCRINE SYSTEM; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; NUTRITION; OBESITY; PATHOGENESIS; PHENOTYPE; POSTMENOPAUSE; PREVALENCE; PRIORITY JOURNAL; REVIEW; SATIETY; STANDARDIZATION; THERMOGENESIS; TREATMENT PLANNING; VISCERA;

ALGORITHMS; CLINICAL PROTOCOLS; FEMALE; HUMANS; INFLAMMATION; OBESITY; PERIMENOPAUSE; POSTMENOPAUSE; SUBCUTANEOUS FAT;

EID: 33644828292     PISSN: 09513590     EISSN: 14730766     Source Type: Journal    
DOI: 10.1080/09513590500453775     Document Type: Review

References (56)

1. Stein JC, Colditz AG. The epidemic of obesity. J Clin Endocrinol Metab 2004;89:2522-2525.
2. Bray AG. Medical consequences of obesity. J Clin Endocrinol Metab 2004;89:2583-2589.
3. Groundy MS. Obesity, metabolic syndrome and cardiovascular disease. J Clin Endocrinol Metab 2004;89:2595-2600.
4. Zimmet P, Alberti G, Shaw J. A new IDF worldwide definition of the metabolic syndrome: the rationale and the results. Diabetes Voice 2005;50:31-33.
5. Karelis AD, St-Pierre DH, Conus F, Rabasa-Lhoret R, Poehlman ET. Metabolic and body composition factors in subgroups of obesity: what do we know? J Clin Endocrinol Metab 2004;89:2569-2575.
6. Conus F, Allison DB, Rabasa-Lhoret R, St-Onge M, St-Pierre DH, Tremblay-Lebeau A, Poehlman ET. Metabolic and behavioral characteristics of metabolically obese but normal weight women. J Clin Endocrinol Metab 2004;89:5013-5020.
7. Dvorak RV, DeNino WF, Ades PA, Poehlman ET. Phenotypic characteristic associated with insulin resistance in metabolically obese but normal-weight young women. Diabetes 1999;48:2210-2214.
8. Sims EA. Are the persons who are obese, but metabolically healthy? Metabolism 2002;50:1499-1504.
9. You T, Ryan AS, Nicklas BJ. The metabolic syndrome in obese postmenopausal women relationship to body composition, visceral fat and inflammation. J Clin Endocrinol Metab 2004;89:5517-5522.
10. Park YW, Zhu S, Palaniappan L, Heshka S, Carnethon MR, Heymsfield SB. The metabolic syndrome: prevalence and associated risk factor findings in the US population from Third National Heath and Nutrition Examination Survey 1988-1994. Arch Intern Med 2003;163:427-436.
11. Tchernof A, Desmeules A, Richard C, Laberge P, Daris M, Mailloux J, Rheaume C, Dupont P. Ovarian hormone status and abdominal visceral adipose tissue metabolism. J Clin Endocrinol Metab 2004;89:3425-3430.
12. Brochu M, Tchernof A, Dionne IJ, Sites CK, Eltabbakh GH, Sims EA, Poehlman ET. What are the physical characteristics associated with a normal metabolic profile despite a high level of obesity in postmenopausal women? J Clin Endocrinol Metab 2001;86:1020-1025.
13. Dubnov G, Brzezinski A, Berry E. Weight control and management of obesity after menopause: the role of physical activity. Maturitas 2003;44:89-101.
14. Nadel I, Cypryk K, Pertynski T, Sobczuk A, Stetkiewicz T. Studies on the incidence and clinical significance of the metabolic syndrome in postmenopausal women in Lodz region. Pol Arch Med Wewn 2001;106:823-828.
15. Lopatynski J, Tokarski S, Mardarowicz G, Niewidziol M. Morbidity in adult rural population in Lublin region. Ann Univ Mariae Curie Sklodowska [Med] 1999;53(Suppl 5):156-160.
16. Milewicz A, Jedrzejuk D, Lwow F, Bialynicka AS, Lopatynski J, Mardarowicz G, Zahorska-Markiewicz B. Prevalence of obesity in Poland. Obes Rev 2005;6:113-114.
17. Pasquali R, Casimirri F, Labate A, Tortelli O, Pascal G, Anconetani B, Gatto MR, Flamia R, Capelli M, Barbara L. Body weight, fat distribution and the menopausal status in women. The VMH Collaborative Group. Int J Obes Relat Metab Disord 1994;18:614-621.
18. Milewicz A, Bidzinska B, Sidorowicz A. Perimenopausal obesity. Gynecol Endocrinol 1996;10:285-291.
19. Gambacciani M, Ciaponi M, Cappagli B. Climacteric modifications in body weight and fat distribution. Climacteric 1999;2:37-44.
20. Milewicz A, Tworowska U, Demissie M. Menopausal obesity - myth or fact? Climacteric 2001;4:273-283.
21. Matthews KA, Abrams B, Crawford S, Miles T, Neer R, Powell LH, Wesley D. Body mass index in mid-life women: relative influence of menopause, hormone use and ethnicity. Int J Obes Relat Metab Disord 2001;25:863-873.
22. Ferrara CM, Lynch NA, Nicklas BJ, Ryan AS, Berman DM. Differences in adipose tissue metabolism between postmenopausal and perimenopausal women. J Clin Endocrinol Metab 2002;87:4166-4170.
23. Poehlman ET. Menopause, energy expenditure and body composition. Acta Obstet Gynecol Scand 2002;81:603-611.
24. Eriksson P, Dahlman I, Ryden M, Hoffstedt J, Arner P. Relationship between β-2 adrenoreceptor gene haplotypes and adipocyte lipolisis in women. Int J Obes Relat Metab Disord 2004;28:185-190.
25. Mattevi VS, Zembrzuski VM, Hutz MH. A resistin gene polymorphism is associated with body mass index in women. Hum Genet 2004;115:208-212.
26. Malacara JM, Perez-Luque EL, Martinez-Garza S, Sanchez-Marin FJ. The relationship of estrogen receptor α polymorphism with symptoms and other characteristics in postmenopausal women. Maturitas 2004;49:163-169.
27. Schuit SC, van Meurs JB, Bergink AP, van der Klift M, Fang Y, Leusink G, Hofman A, van Leeuwen JP, Uitterlinden AG, Pols HA. Weight in pre- and postmenopausal women is influenced by estrogen receptor α gene polymorphism. J Clin Endocrinol Metab 2004;89:303-309.
28. Deng HW, Li J, Li JL, Dowd R, Davies KM, Johnson M, Gong G, Deng H, Recker RR. Association of estrogen receptor α genotypes with body mass index in normal healthy postmenopausal Caucasian women. J Clin Endocrinol Metab 2000;85:2748-2751.
29. Giusti V, Suter M, Verdumo C, Gaillard RC, Burckhardt P, Pralong FP. Molecular determinants of human adipose tissue: differences between visceral and subcutaneous compartments in obese women. J Clin Endocrinol Metab 2004;89:1379-1384.
30. Freedland ES. Role of a critical visceral adipose tissue threshold (CVATT) in metabolic syndrome: implications for controlling dietary carbohydrates: a review. Nutr Metab (Lond) 2004;5:12.
31. Wajchenberg BL. Subcutaneous and visceral adipose tissue: their relation to the metabolic syndrome. Endocr Rev 2000;21:697-738.
32. Mayes JS, Watson GH. Direct effects of sex hormones on adipose tissues and obesity. Obes Rev 2004;5:197-216.
33. Randolph JF Jr, Sowers M, Gold EB, Mohr BA, Luborsky J, Santoro N, McConnell DS, Finkelstein JS, Korenman SG, Matthews KA, et al. Reproductive hormones in the early menopausal transition: relationship to ethnicity, body size and menopausal status. J Clin Endocrinol Metab 2003;88:1516-1522.
34. dos Reis CM, de Melo NR, Meirelles ES, Vezozzo DP, Halpern A. Body composition, visceral fat distribution and fat oxidation in postmenopausal women using oral and transdermal estrogen. Maturitas 2003;46:59-68.
35. Schimizu H, Shimomura Y, Nakanishi Y. Estrogen increases in vivo leptin production in rats and human subjects. J Endocrinol 1997;154:285-292.
36. Rosenbaum M, Nicolson M, Hirsh J. Effects of gender, body composition and menopause on plasma concentrations of leptin. J Clin Endocrinol Metab 1996;81:3224-3427.
37. Milewicz A, Bidzinska B, Mikulski E, Demissie M, Tworowska U. Influence of obesity and menopausal status on serum leptin, cholecystokinin, galanin and neuropeptide Y levels. Gynecol Endocrinol 2000;14:196-203.
38. Howard BV, Adams-Campbell L, Allen C, Black H, Passaro M, Rodabough RJ, Rodriguez BL, Safford M, Stevens VJ, Wagenknecht LE. Insulin resistance and weight gain in postmenopausal women of diverse ethnic groups. Int J Obes Relat Metab Disord 2004;28:1039-1047.
39. Franco C, Brandberg J, Lonn L, Andersson B, Bengtsson BA, Johannsson G. Growth hormone treatment reduces abdominal visceral fat in postmenopausal women with abdominal obesity: 12 months placebo-controlled trial. J Clin Endocrinol Metab 2005;90:1466-1474.
40. MacEven EG, Kurzman ID. Obesity in the dog: role of the adrenal steroid dehydroepiandrosterone (DHEA). J Nutr 1991;121:51-55.
41. Coleman DL, Leiter EH, Schweizer RW. Therapeutics effects of dehydroepiandrosterone in diabetic mice. Diabetes 1982;31:830-833.
42. Bednarek-Tupikowska G, Milewicz A, Kossowska B, Bohdanowicz-Pawlak A, Sciborski R. The influence of DHEA on serum lipids, insulin and sex hormone levels in rabbits with induced hypercholesterolemia. Gynecol Endocrinol 1995;9:23-28.
43. Morales AJ, Nolan JJ, Nelson JC. Effects of replacement doses of dehydroepiandrosterone in men and women of advancing age. J Clin Endocrinol Metab 1994;78:1360-1367.
44. Milewicz A, Jedrzejuk D, Bohdanowicz-Pawlak A, Medras M. Metabolic and hormonal changes after DHEA treatment. In: Aso T, Yanairharia T, Taketani Y, editors. The 9th International Menopause Society world congress on the menopause, Yokohama (Japan). Bologna: Moduzzi Editore; 1999. pp 215-220.
45. Jedrzejuk D, Medras M, Milewicz A, Demissie M. Dehydroepiandrosterone replacement in healthy men with age-related decline of DHEA-S: effects on fat distribution, insulin sensitivity and lipid metabolism. Aging Male 2003;6:2-6.
46. Matsukawa T, Sugiyama Y, Watanabe T. Gender difference in age-related changes in muscle sympathetic nerve activity in healthy subjects. Am J Physiol 1998;275:R1600-R1604.
47. Jones PP, Davy KP, Alexander S. Age-related increase in muscle sympathetic nerve activity is associated with abdominal adiposity. Am J Physiol 1997;272:E976-E980.
48. Acheson KJ, Ravussin E, Schoeller DA, Christin L, Bourquin L, Baertschi P, Danforth E Jr, Jequier E. Two-week stimulation or blockade of the sympathetic nervous system in man: influence on body weight, body composition and twenty four-hour energy expenditure. Metabolism 1988;37:91-98.
49. Spraul M, Ravussin E, Fontvieille AM. Reduced sympathetic nervous activity. A potential mechanism predisposing to body weight gain. J Clin Invest 1993;92:1730-1735.
50. Ryan AS, Nicklas BJ. Reductions in plasma cytokine levels with weight loss improve insulin sensitivity in overweight and obese postmenopausal women. Diabetes Care 2004;27:1699-1705.
51. Milewicz A, Demissie M, Zatonska K, Jedrzejuk D, Tworowska U, Ilow R, Biernat J. Influence of dietary and genetic factors on metabolic status in obese and lean postmenopausal women. Gynecol Endocrinol 2003;17:333-338.
52. Milewicz A, Horst-Sikorska W, Zatonska K, Jedrzejuk D, Demissie M, Bolanowski M. Selected cytokines and growth factors and obesity on postmenopausal women. Gynecol Endocrinol 2001;15(Suppl.5):10.
53. Mantzoros C, Petridou E, Dessypris N, Chavelas C, Dalamaga M, Alexe DM, Papadiamantis Y, Markopoulos C, Spanos E, Chrousos G, et al. Adiponectin and breast cancer. J Clin Endocrinol Metab 2004;89:1102-1107.
54. Dal Maso L, Augustin LS, Karalis A, Talamini R, Franceschi S, Trichopoulos D, Mantzoros CS, La Vecchia C. Circulating adiponectin and endometrial cancer risk. J Clin Endocrinol Metab 2004;89:1160-1163.
55. The IMS Executive Committee. Guidelines for hormone treatment of women in the menopausal transition and beyond. Maturitas 2005;51:15-21.
56. Barlow DH. Menopause and HRT - the state of the art in Europe. Maturitas 2005;51:40-48.